Other product sales declined 40.3% to $4.0 million. Adjusted selling, general and administrative (SG&A) expenses rose 23.6% to $137.7 million due to higher expenses related to business expansion, including costs related to continued launch of Vyxeos in the United States and potential launch of Vyxeos in the EU and JZP-110 in the United States. Adjusted research and development (R&D) expenses increased 45.7% to $51.4 million, mainly due to escalated expenses related to the company's pipeline and regulatory activities. 2018 Guidance Despite the better-than-expected second-quarter results, Jazz maintained its earnings and sales guidance for 2018. Though the guidance range for Xyrem's sales was slightly raised, the company lowered its full-year expectations for its newest drug, Vyxeos. Jazz expects earnings in the range of $12.75-$13.25 per share. Total revenues are expected in the range of $1.88-$1.93 billion. Total product sales are predicted in the range of $1.87-$1.91 billion in 2018.